NEW YORK, February 27, 2017 /PRNewswire/ --
This morning's research directs the attention of Stock-Callers.com tothe following Generic Drugs stocks: Zoetis Inc. (NYSE: ZTS), Mallinckrodt PLC (NYSE: MNK), Akorn Inc. (NASDAQ: AKRX), and MYOS RENS Technology Inc. (NASDAQ: MYOS). These companies belong to the Healthcare sector, which edged higher just before the closing
New Jersey headquartered Zoetis Inc.'s stock climbed 0.56%, finishing last Friday's trading session at $53.88. A total volume of 4.82 million shares was traded, which are above their three months average volume of 3.32 million shares. The Company's shares have gained 8.78% over the previous three months and 0.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.16% and 6.62%, respectively. Additionally, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 46.07.
On February 15th, 2017, Zoetis announced that the European Commission has granted the Company a license for Stronghold® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice, and gastrointestinal nematodes and prevents heartworm disease in cats. See our free and comprehensive research report on ZTS at:
Shares in the UK-based Mallinckrodt PLC ended at $53.38, down 2.00% from the last trading session. The stock recorded a trading volume of 1.71 million shares. The Company's shares have advanced 13.36% in the past month and 7.15% on an YTD basis. The stock is trading 5.16% above its 50-day moving average. Moreover, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, the Middle East, Africa, and internationally, have an RSI of 58.86.
On February 07th, 2017, Mallinckrodt reported results for the transition period from October 01st, 2016 to December 30th, 2016. The last quarter of calendar year 2016 was the planned transition period as the Company aligns to a calendar-based financial year. Mallinckrodt will continue its "4/5/4" reporting convention with the first fiscal year ending December 29th, 2017. Mallinckrodt's net sales were $829.9 million in the transition period, up 2.3% on a y-o-y basis. The Company's GAAP gross profit was $445.8 million in the transition period with gross profit as a percentage of net sales of 53.7% compared to 55.6% on a y-o-y basis.
On February 22nd, 2017, research firm Canaccord Genuity initiated a 'Buy' rating on the Company's stock, with a target price of $91 per share. MNK free research report PDF is just a click away at:
On Friday, shares in Illinois headquartered Akorn Inc. recorded a trading volume of 1.46 million shares. The stock declined 1.39%, closing the day at $21.28. The Company's shares have gained 6.99% in the last one month. The stock is trading 1.27% above its 50-day moving average. Additionally, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals in the US and internationally, have an RSI of 53.28.
On February 06th, 2017, Akorn announced plans to issue a press release on March 01st, 2017 outlining Q4 and full year 2016 results. In addition, the Company will host a conference call at 10:00 am ET on the same day to discuss these results. Sign up for your complimentary report on AKRX at:
MYOS RENS Technology
At the close of trading on Friday, shares in New Jersey-based MYOS RENS Technology Inc. recorded a trading volume of 256,711 shares. The stock finished the session 7.12% lower at $2.74. The Company's shares have surged 68.09% in the previous three months and 132.19% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.28% and 41.75%, respectively. Furthermore, shares of MYOS RENS Technology, which focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue, have an RSI of 45.57.
On February 14th, 2017, MYOS announced that its Board of Directors has adopted a shareholder rights plan. The Board adopted the Rights Plan to ensure that the Board remains in the best position to perform its fiduciary duties and enable all of the Company's shareholders to receive fair and equal treatment. The rights will expire on February 14th, 2020. Register for free on Stock-Callers.com and download the latest research report on MYOS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Endoscopic Retrograde Cholangio-Pancreatography uses endoscopy and fluoroscopic imaging for ...
Wolff-Parkinson-White syndrome is caused due to an extra electrical pathway in the heart, which ...
Discover the amazing health benefits of this ''under-valued'' vegetable called leek. Know the ...View All